Ponad 7000 publikacji medycznych!
Statystyki za 2021 rok:
odsłony: 8 805 378
Artykuły w Czytelni Medycznej o SARS-CoV-2/Covid-19

Poniżej zamieściliśmy fragment artykułu. Informacja nt. dostępu do pełnej treści artykułu
© Borgis - New Medicine 2/2011, s. 61-66
*Zsuzsanna Kovács1, Adrien Pigniczkiné Rigó2, Éva Szabó3, Árpád Sebestyén4, Mária Hoyer1, Emőke Fülöp1, Nóra Garamvölgyi1, Imre András Török1, Zsolt Petke1
1Semmelweis University, Faculty of Health Sciences, Budapest
Head of Faculty: Prof. dr Judit Mészáros
2Eötvös Loránd University, Faculty of Pedagogy and Psychology, Budapest
Head of Faculty: Prof. dr Zsolt Demetrovics
3National Institute of Oncology, Department of Radiodiagnostics
Head of Department: Prof. dr Mária Gődény
4 Source of Health Fundation
Head of Fundation: Prof. dr Mihály Réger
Aim. The aim of the study is to examine the prevalence of depression and anxiety, and their correlation to quality of life in patients with malignant breast tumour.
Material and methods. The research has been carried out in Budapest at the Department of Radiological Diagnostics of the National Institute of Oncology. 221 women have participated in the study, all suffering from breast cancer. The Shortened Beck Depression Inventory, the Spielberger’s State-Trait Anxiety Inventory and the EORTC QLQ C30 BR23 quality of life questionnaire have been used for the research.
Results. The prevalence of clinical depression in the study-sample is 11.5% of the cases, 64.3% of the patients had mild depression (mean 12.97, std. deviation: 4.63). Concerning anxiety, 18.8% of the patients had severe and 13.6% had subclinical trait-anxiety (mean: 43.35, std. deviation: 10.31). There was a significant correlation between depression and anxiety (r=0.758, p=0.001). Both psychological disorders are reliable predictors for global, functional and symptom ratings of the quality of life, determined by the EORTC QLQ C30 BR23 questionnaire.
Conclusion. The recognition of the presence of anxiety and depression, and their medical and psychological support are crucial as they fundamentally determine the patient’s quality of life and can hugely help encourage the patient’s cooperation and evoke the fighting spirit.

Cancer is characteristically accompanied by anxiety and depression. Even if the disease is detected at an early stage and the prognosis is good, the patient will experience deep emotional pain and excessive anxiety. Cancer, despite the fact that the majority of patients are considered chronically ill, still constitutes a deadly threat.
Medical literature clearly demonstrates the presence of anxiety and depression during cancerous affections. Polsky inducted a large sample research involving more than 8,000 patients, in which he analysed the presence of depression in the most common conditions (cancer, cardiovascular conditions, chronic lung disease, arthritis, diabetes). According to his findings, patients with cancer had the highest rate of depression. He measured clinical depression in 13% of the cases (1).
Concerning the rates of psychological disorders, various data can be found. Some authors suggest that the presence of psychological distress is 50%; these are mainly adjustment difficulties accompanied by anxiety and depression (2). Derogatis studied the prevalence of psychiatric disorders in cancer patients and found psychological disorders in 47% of the cases (3). Another research team have also registered related symptoms in 50% of patients; their symptoms being hopelessness, resignation, depression, and in terminal cases an excessive desire for death (4).
Similar results can be found in women suffering from breast cancer. In a large cohort of 4,496 patients the prevalence of depression was estimated to be around 52% (5).
Numerous authors have registered similar symptoms of psychological morbidities, such as anxiety, depression, stress, distress, (5, 6, 7), while others reported difficulty in adjustment and decreased social interactions (8). Such responses may arise from the fear of pain, fear of recurrence, and from the unpleasant treatment side-effects (9).
A recent study suggests however that the number of patients approaching threshold for depressive and anxiety disorders is close to 50% in the first year after diagnosis, dropping rapidly in the second year to 25% and sustaining a further gradual decrease over the five-year study period to 15% in the fifth year (10). A review of 37 studies on the epidemiology of major depression in women with breast cancer suggested a rate of 10% to 25% (6). Close correlation is found between depression and anxiety: about one third (35%) of the patients reported anxiety or depression, or both, which did not significantly change over five years of follow up (11). This wide variation in rates of psychological disorders may be attributed to methodological differences across studies (cross-section researches, experimental group-studies). The stage of the illness and the circumstances of the research may also influence the outcome, in the same way as the use of different tools and different diagnostic criteria or even the focus of the study (6, 7, 12, 13).
Concerning the subject, only a few studies have been conducted in Hungary. There has been a national representative study carried out as a part of the Hungarostudy 2002, surveying the physical and mental health of the adult population of Hungary, and the relation between health indicators and the environmental, social and economic background. According to their research results the incidence of clinically significant depression rate in women affected with cancer was 28.5%, while in men it showed 27.4%. (14) A study conducted in Transylvania examined the prevalence of depression in correlation with numerous factors (demographic, medical, lifestyle and psychosocial). The results suggested that about 50% of the inpatients questioned suffered from clinical depression (15). Riskó basing on her clinical experience, reports similar results (16).
The appearance and the degree of anxiety and depression are correlated with numerous factors: type of cancer, its seriousness, chances of curability, the impact of symptoms (associated with various treatments) on the quality of patient’s life (10), the patient’s social support network, psychosocial background, length of time passed since the diagnosis, but even the characteristics of the premorbid personality, and the patient’s way of coping (6, 13, 17); all factors influencing the appearance of emotional distress, depression and anxiety. On the other hand, the high levels of anxiety observed in patients can influence their life, their condition and the management of their illness in many different ways. There is a so-called Kindling phenomenon which is characteristically present in patients: it is typical that before each control visit patients feel more uneasy, uncertain; anxiety and depression become more prominent, the same ways as deterioration may appear after repeated surgical interventions, treatments or a relapse (18). The prevalence of depression has a very strong deteriorative affect on the quality of life of the patient, puts a burden on the patient’s social relations and, at the same time, interferes with her/his active coping attitude and increases the chances of the recurrence (19). Kepplinger and Steige, in their comprehensive study of development of family and social relations, also researching the levels and characteristics of distress of the relatives, have come to a conclusion that the levels of stress, anxiety and depression in the patient’s relatives are similar to those of the patient with cancer (20).
The recognition of the presence of anxiety and depression, and their medical and psychological support are crucial. They fundamentally determine the patient’s quality of life, and can hugely help encourage the patient’s cooperation and evoke the fighting spirit.
In 2009-2010 a comprehensive psycho-oncology research was conducted, intending to develop a complex, complementary rehabilitation method in addition to the traditional medical cancer treatment, in order to improve the health and quality of life, strengthen coping abilities, and increase the life expectancy of patients suffering from cancer. In the first step of this study, cross-sectional studies have been carried out, and a randomized sample has been introduced to a complex, psychosocial intervention program.
The presented study explores some of the outcomes of the cross-sectional research:
– the prevalence of anxiety and depression,
– the correlation of anxiety and depression to quality of life.
The assessed sample
The sample involved 221 female patients suffering from malignant breast tumour (C50), who agreed to cooperate and who at the time were actually undergoing a treatment for active cancer. The research was carried out in Budapest at the Department of Radiological Diagnostics of the National Institute of Oncology, with an official approval from the Ethical Committee of the Institute.
We used an eight-page self-assessment form filled in by each patient individually, taking about 50 minutes in each case. The questionnaires have been completed within the frames of the mammographic investigation.

Powyżej zamieściliśmy fragment artykułu, do którego możesz uzyskać pełny dostęp.
Mam kod dostępu
  • Aby uzyskać płatny dostęp do pełnej treści powyższego artykułu albo wszystkich artykułów (w zależności od wybranej opcji), należy wprowadzić kod.
  • Wprowadzając kod, akceptują Państwo treść Regulaminu oraz potwierdzają zapoznanie się z nim.
  • Aby kupić kod proszę skorzystać z jednej z poniższych opcji.

Opcja #1


  • dostęp do tego artykułu
  • dostęp na 7 dni

uzyskany kod musi być wprowadzony na stronie artykułu, do którego został wykupiony

Opcja #2


  • dostęp do tego i pozostałych ponad 7000 artykułów
  • dostęp na 30 dni
  • najpopularniejsza opcja

Opcja #3


  • dostęp do tego i pozostałych ponad 7000 artykułów
  • dostęp na 90 dni
  • oszczędzasz 28 zł
1. Polsky D, Doshi JA, MarcusS et al.: Long-Term Risk For Depressive Symptoms After A Medical Diagnosis. Archives Of Internal Medicine 2005;165: 1260-1266. 2. Massie MJ: Prevalence of depression in patients with cancer. JNCI Monographs, 2004; 32: 57-71. 3. Derogatis LR, Morrow GR, Fetting J Et al.: The prevalence of psychiatric disorders among cancer patients. Journal of the American Medical Association 1983; 249: 751-757. 4. Breitbart W, Rosenfeld B, Pessin H Et al.: Depression, Hopelessness, and Desire for Hastened Death in Terminally Ill Patients With Cancer. Journal of the American Medical Association 2000; 284: 2907-2911. 5. Zabora J, Brintzenhofe K, Curbow B et al.: The prevalence of psychological distress by cancer site. Psycho-oncology 2001; 10(1): 19-28. 6. Fann J: Major depression after breast cancer: a review of epidemiology and treatment. General Hospital Psychiatry 2008; 30 (2): 112-26. 7. Reich M, Lesur A, Perdrizet-Chevallier C: Depression, quality of life and breast cancer: a review of the literature. Breast Cancer Research and Treatment 2008; 110(1): 9-17. 8. Vos PJ, Visser AP, Garssen B et al.: Effects of delayed psychosocial interventions versus early psychosocial interventions for women with early stage breast cancer. Patient Education and Counseling 2006; 60(2): 212-221 9. Reddick BK, Nanda JP, Campbell L et al.: Examining the influence of coping with pain on depression, anxiety, and fatigue among women with breast cancer. Journal of Psychosocial Oncology 2005;23(2-3): 137-57. 10. Burgess C, Cornelius V, Love S et al.: Depression and anxiety in women with early breast cancer: five year observational cohort study. BMJ 2005; 330(7493): 702-5 . 11. Hopwood P, Sumo G, Mills J et al.: The course of anxiety and depression over 5 years of follow up and risk factors in women with early breast cancer: Results from the UK Standardisation of Radiotherapy Trials (START). Breast 2010;19 (2): 84-91. 12. Chochinov HM, Wilson KG, Enns M, Lander S: Prevalence of depression in the terminally ill: effects of diagnostic criteria and symptom threshold judgments. The American Journal of Psychiatry 1994; 151: 537-40. 13. Baider L, Andritsch E, Uziely B et al.: Effects of age on coping and psychological distress in women diagnosed with breast cancer: review of literature and analysis of two different geographical settings. Critical Reviews in Oncology/Hematology 2003; 46(1): 5-16. 14. Dégi L. Csaba: Pszichoszociális kockázati tényezők szerepe a daganatos megbetegedésekben, 2008. [In:] Kopp, M. (szerk.), Magyar lelkiállapot (pp. 557-568). Semmelweis Kiadó, Budapest . 15. Dégi L. Csaba: A depresszió prevalenciája az onkológiai ellátásban Erdélyben. Kórházban kezelt daganatos betegek körében végzett multicentrikus felmérés Beck-féle depresszió önértékelő kérdőívvel, Erdélyi pszichológiai szemle 2009; 4, 299-321 16. Riskó Á: Bevezetés az onkopszichológiába. Animula, Budapest 1999. 17. Barsevick AM, Sweeney C, Haney E, Chung E: A systematic qualitative analysis of psychoeducational interventions for depression in patients with cancer. Oncology Nursing Forum 2002; 29(1): 73-87. 18. Veres Zs: A daganatos betegségek lehetséges pszichológiai és pszichiátriai tünetei, 2006. [In:] Horti, J.,Riskó, Á. (szerk.), Onkopszichológia a gyakorlatban (pp. 203-209), Medicina, Budapest. 19. Greer S, Morris T, Pettingale KW: Psychological response to breast cancer: effect on outcome. Lancet 1979; ii: 785-7. 20. Kepplinger J, Steige R: Psychosoziale Belastungen und soziale Unterstützung bei Partnern von Krebskranken. [In:] Kállai J, Varga J, Oláh A (szerk): Egészségpszichológia a gyakorlatban, 2007, Medicina, Budapest. 21. Rózsa S, Szádóczky E, Füredi J: A Beck Depresszió Kérdôív rövidített változatának jellemzôi hazai mintán. Psychiatria Hungarica 2001; 16: 384-402. 22. Sipos K, Sipos M, Spielberger CD: A State-Trait Anxiety Inventory (STAI) magyar változata. [In:] Mérei F, Szakács F (szerk.): Pszichodiagnosztikai vademecum I/2. Nemzeti Tankönyvkiadó, Budapest 1994; 123-148. 23. Spielberger CD, Gorsuch RL, Lushene RE: Manual for the State-Trait Anxiety Inventory. Consulting Psychologists Press 1970; Palo Alto, CA. 24. Stauder A, Kovacs M: Anxiety symptoms in allergic patients: Identification and risk factors. Psychosom Med 2003; 65, 816-823. 25. Aaronson NK, Ahmedzai S, Bergman B et al.: The European Organisation for Research and Treatment of Cancer QLQ-C30: a uality of life instrument for use in international clinical trials in oncology. Journal of National Cancer Institute 1993; 85, 365-367. 26. Aaronson NK, Ahmedzai S, Bullinger M et al.: The EORTC Core Quality of Life Questionnaire: interim results of an international field study. [In:] Osoba D. (ed.), Effect of Cancer on Quality of Life (Boca Raton, FL: CRC Press) 1991; pp. 185-203.
otrzymano: 2011-04-05
zaakceptowano do druku: 2011-05-18

Adres do korespondencji:
*Zsuzsanna Kovács
Semmelweis University Faculty of Health Sciences
1085 Budapest, Vas u. 17
tel.: +36 30 9425 283
e-mail: kovacszs@se-etk.hu

New Medicine 2/2011
Strona internetowa czasopisma New Medicine